A practical reference on Stenabolic: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-20. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
== Contraindications == Dihydroergotamine is contraindicated with potent CYP3A4 inhibitors, like macrolide antibiotics. Contraindications for dihydroergotamine include: pregnancy, kidney failure or liver failure, coronary, cerebral, and peripheral vascular disease, hypersensitivity reactions, sepsis, and uncontrolled hypertension.
Examples of important CYP3A4 modulators which are expected to interact with suvorexant include the strong CYP3A4 inhibitors boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, and telithromycin (concomitant use not recommended); the moderate CYP3A4 inhibitors amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, dronedarone, erythromycin, fluconazole, fluvoxamine, fosamprenavir, grapefruit juice, imatinib, and verapamil (lower doses of suvorexant recommended); and the strong CYP3A4 inducers apalutamide, carbamazepine, efavirenz, enzalutamide, phenytoin, rifampin, and St. John's wort (expected to decrease suvorexant effectiveness). Coadministration of suvorexant with other CNS depressants, such as alcohol, benzodiazepines, opioids, and tricyclic antidepressants, may increase the risk of CNS depression and daytime impairment. Alcohol and suvorexant do not appear to interact in terms of pharmacokinetics but consumption of alcohol in combination with suvorexant is not advised due to additive CNS depression. Dosage adjustment may be necessary when suvorexant is combined with other CNS depressants. Use of suvorexant in combination with other medications used in the treatment of insomnia is not recommended. Suvorexant is not expected to cause clinically meaningful inhibition or induction of various cytochrome P450 enzymes and drug transporters.
== Missile Impact Location System == From 1958 through 1960 the United States installed the Missile Impact Location System (MILS) in the Navy-managed Pacific Missile Range, later the Air Force–managed Western Range, to localize the splashdowns of test missile nose cones. MILS was developed and installed by the same entities that had completed the first phase of the Atlantic and U.S. West Coast SOSUS systems. A MILS installation, consisting of both a target array for precision location and a broad ocean area system for good positions outside the target area, was installed at Eniwetok as part of the system supporting intercontinental ballistic missile (ICBM) tests. Other Pacific MILS shore terminals were at the Marine Corps Air Station Kaneohe Bay supporting intermediate-range ballistic missile (IRBM) tests with impact areas northeast of Hawaii and the other ICBM test support systems at Midway Island and Wake Island.
Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an enzyme that in humans is encoded by the ERAP1 gene. This M1 zinc aminopeptidase is involved in the antigen processing and presentation pathway. ERAP1 is mainly located in the endoplasmic reticulum (ER), where it trims peptides at their N-terminus, adapting them for presentation by MHC class I molecules (MHC-I).
Sources: en.wikipedia.org
=== Other uses in performing arts === "Access all areas", a form of backstage pass Association of Amateur Artists, a theatre association in Peru Asia Artist Awards, the South Korean annual award ceremony hosted by Star News 98.9 FM (Brisbane), also known as Triple A Murri Country, an Australian community radio station
Production of the BG Familia mostly ended on 24 May 1994, although the 1.3 L hatchback was kept in production until October 1996 as there was originally no 1.3 L option in the following generation. In Australia and South America, the BG saloon continued to be sold until 1996 as a more affordable alternative to the newer BH model. The Indonesian market 323 was assembled locally starting in 1989 and was available only as a saloon. It was sold in a single trim called Interplay, powered by a carbureted 1.6 L SOHC engine mated to a 5-speed manual or a rare 4-speed automatic transmission. Unique to this market, the 323 came standard with a digital speedometer from the Eunos 100, a feature that was optional in Japan. Around late 1994, a special edition called Interplay Executive was introduced featuring the facelifted bumpers and bigger 14-inch steel wheels with hubcaps, but it also loses the digital speedometer. Also a few months later in this year when the newer BH model was introduced, BG model production was extended until 1997, primarily for the taxi fleet market. This fleet version had its premium features removed and an optional 1.3 L engine. In China, Haima—a joint venture between Hainan Auto Works and Mazda—began manufacturing the BG saloon on the island of Hainan in 1994. The saloon was initially marketed as the HMC6430, powered by a 1.3 L B3 engine. Another model, the GH7160, was released shortly thereafter with a 1.6 L SOHC B6 engine, manufactured at Haima's branch factory in Beihai, Guangxi.
=== Sentencing and imprisonment === On August 16, 2010, Judge Keenan sentenced Banki to 30 months in prison. Shortly after being sentenced Banki filed for appeal. The Iranian American Bar Association along with 10 other advocacy and civil rights groups filed a separate amicus brief with the United States Court of Appeals for the Second Circuit. The brief argued that U.S.-Iran sanctions "are not aimed at the Iranian people, and therefore they contain exemptions permitting certain humanitarian transactions and family remittances." For about 11 months (from January 7, 2010, through December 1, 2010) Banki was held in high and maximum security detention centers in Manhattan and Brooklyn (MCC and MDC) with BOP# 63037-054. For the month of December in 2010, Banki was transferred to the Taft Correctional Institute's deportation prison outside of Bakersfield in California. In January 2011, Banki was transferred to the lower security Taft prison where he remained pending the appellate decision. Upon release Banki had served 665 days, nearly 22 months in prison.
=== Munc13/UNC-13 activation === Diacylglycerol has been shown to exert some of its excitatory actions on vesicle release through interactions with the presynaptic priming protein family Munc13 coded by human genes UNC13A and UNC13B. Binding of DAG to the C1 domain of UNC13 increases the fusion competence of synaptic vesicles resulting in potentiated release. Diacylglycerol can be mimicked by the tumor-promoting compounds phorbol esters.
=== Early history === More than two thousand years ago the Scythians lived on the banks of the river Don. Many Scythian tombs have been found in this area. Subsequently, the area was inhabited by the Khazars and the Polovtsians. From the 16th to the 18th centuries the steppes of the Don River were part of "the Wild Field" (Russian: Дикое Поле). In the late Middle Ages the area was under the general control of the Golden Horde, and numerous Tatar (especially Crimean Tatar) armed groups roamed there, attacking and enslaving merchants and settlers. The first Christians to settle on the territories around the Don were the Jassi and Kosogi tribes of the Khazar Kaghanate of the 7th to 10th centuries. After the fall of the Golden Horde in 1480, more colonists started to expand onto this land from the Novgorod Republic after the Battle of Shelon (1471), and from the neighboring Principality of Ryazan. Until the end of the 16th century, the Don Cossacks inhabited independent free territories.
Sources: en.wikipedia.org
Within a coral head, the genetically identical polyps reproduce asexually, either by budding (gemmation) or by dividing, whether longitudinally or transversely. Budding involves splitting a smaller polyp from an adult. As the new polyp grows, it forms its body parts. The distance between the new and adult polyps grows, and with it, the coenosarc (the common body of the colony). Budding can be intratentacular, from its oral discs, producing same-sized polyps within the ring of tentacles, or extratentacular, from its base, producing a smaller polyp. Division forms two polyps that each become as large as the original. Longitudinal division begins when a polyp broadens and then divides its coelenteron (body), effectively splitting along its length. The mouth divides and new tentacles form. The two polyps thus created then generate their missing body parts and exoskeleton. Transversal division occurs when polyps and the exoskeleton divide transversally into two parts. This means one has the basal disc (bottom) and the other has the oral disc (top); the new polyps must separately generate the missing pieces. Asexual reproduction offers the benefits of high reproductive rate, delaying senescence, and replacement of dead modules, as well as geographical distribution.
== Medical uses == Acemetacin has proven effective in the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and other kinds of rheumatoid inflammation, as well as in post-operative and post-traumatic pain and attack of gout. Application of a single dose of acemetacin for post-operative pain is not well supported by studies.
Basement membranes are characteristic of eumetazoans, including diploblastic animals, and have also been identified in homoscleromorph sponges. The homoscleromorph were found to be sister to diploblasts in some studies, making the membrane originate once in the history of life. But more recent studies have disregarded diploblast-homoscleromorph group, so other sponges may have lost it (most probable) or the origin in the two groups may be separate.
The principal substrate of physiological importance of glucokinase is glucose, and the most important product is glucose-6-phosphate (G6P). The other necessary substrate, from which the phosphate is derived, is adenosine triphosphate (ATP), which is converted to adenosine diphosphate (ADP) when the phosphate is removed. The reaction catalyzed by glucokinase is shown in the inset. ATP participates in the reaction in a form complexed to magnesium (Mg) as a cofactor. Furthermore, under certain conditions, glucokinase, like other hexokinases, can induce phosphorylation of other hexoses (6 carbon sugars) and similar molecules. Therefore, the general glucokinase reaction is more accurately described as:
== See also == Breast hypertrophy – Rare human disease Male bra – Pieces of clothing that fit tightly around the skinPages displaying short descriptions of redirect targets Male lactation – Production of milk in male mammals Mammoplasia – Normal or spontaneous enlargement of breasts
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.